Skip to main content

Advertisement

SpringerLink
Log in

Serum levels of lipocalin-2 in patients with Parkinson’s disease

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Background

Parkinson’s disease (PD) is the second most common neurodegenerative disease. Evidence has shown that lipocalin-2 (LCN2) is involved in the pathological process of PD. We aimed to explore whether serum levels of LCN2 could be a biomarker of PD.

Methods

We recruited consecutive PD patients and healthy controls (HC) in our hospital from June 2020 to July 2020. Serum LCN2 levels were detected using the LCN2 enzyme-linked immunosorbent assay (ELISA) kit. The motor section of the Unified Parkinson’s Disease Rating Scale (UPDRS III) and the Hoehn and Yahr Staging Scale (H&Y) were assessed on admission to evaluate disease severity in patients with PD. Cognitive status was measured by the Montreal Cognitive Assessment (MoCA).

Results

We finally recruited 75 patients, including 40 PD patients and 35 HC. Serum LCN2 levels were not significantly increased in PD patients compared with HC (4.9 [− 0.7 to 18.6] vs 1.9 [− 1.5 to 16.9] ng/mL, P = 0.33). Besides, there was no significant difference in LCN2 levels between patients at early and advanced stage of PD (P = 0.75), as well as between cognitively impaired PD patients, PD patients with normal cognition, and HC (P = 0.30). Moreover, LCN2 had no correlation with disease duration (r =  − 0.1, P = 0.37), UPDRS III score (r = 0.07, P = 0.65), and MoCA score (r = 0.221, P = 0.17).

Conclusions

Overall, our study suggests that serum LCN2 levels may not be a biomarker for PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet (London, England) 386(9996):896–912. https://doi.org/10.1016/s0140-6736(14)61393-3

    Article  CAS  Google Scholar 

  2. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424

    Article  PubMed  Google Scholar 

  3. Pfeiffer RF (2016) Non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 22(Suppl 1):S119-122. https://doi.org/10.1016/j.parkreldis.2015.09.004

    Article  PubMed  Google Scholar 

  4. Braak H, Del Tredici K (2017) Neuropathological staging of brain pathology in sporadic Parkinson’s disease: separating the wheat from the chaff. J Parkinsons Dis 7(s1):S71–S85. https://doi.org/10.3233/jpd-179001

    Article  PubMed  PubMed Central  Google Scholar 

  5. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510–518. https://doi.org/10.1016/j.nbd.2009.11.004

    Article  CAS  PubMed  Google Scholar 

  6. Hirsch EC, Standaert DG (2020) Ten unsolved questions about neuroinflammation in Parkinson’s disease. Mov Disord. https://doi.org/10.1002/mds.28075

    Article  PubMed  Google Scholar 

  7. Gelders G, Baekelandt V, Van der Perren A (2018) Linking neuroinflammation and neurodegeneration in Parkinson’s disease. J Immunol Res 2018:4784268. https://doi.org/10.1155/2018/4784268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Moschen AR, Adolph TE, Gerner RR, Wieser V, Tilg H (2017) Lipocalin-2: a master mediator of intestinal and metabolic inflammation. Trends Endocrinol Metab 28(5):388–397. https://doi.org/10.1016/j.tem.2017.01.003

    Article  CAS  PubMed  Google Scholar 

  9. Ferreira AC, Dá Mesquita S, Sousa JC, Correia-Neves M, Sousa N, Palha JA, Marques F (2015) From the periphery to the brain: Lipocalin-2, a friend or foe? Prog Neurobiol 131:120–136. https://doi.org/10.1016/j.pneurobio.2015.06.005

    Article  CAS  PubMed  Google Scholar 

  10. Kim BW, Jeong KH, Kim JH, Jin M, Kim JH, Lee MG, Choi DK, Won SY, McLean C, Jeon MT, Lee HW, Kim SR, Suk K (2016) Pathogenic upregulation of glial lipocalin-2 in the Parkinsonian dopaminergic system. J Neurosci 36(20):5608–5622. https://doi.org/10.1523/jneurosci.4261-15.2016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Eidson LN, Kannarkat GT, Barnum CJ, Chang J, Chung J, Caspell-Garcia C, Taylor P, Mollenhauer B, Schlossmacher MG, Ereshefsky L, Yen M, Kopil C, Frasier M, Marek K, Hertzberg VS, Tansey MG (2017) Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease. J Neuroinflammation 14(1):164. https://doi.org/10.1186/s12974-017-0935-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Eruysal E, Ravdin L, Kamel H, Iadecola C, Ishii M, Zetterberg H (2019) Plasma lipocalin-2 levels in the preclinical stage of Alzheimer’s disease. Alzheimers Dement 11(1):646–653. https://doi.org/10.1016/j.dadm.2019.07.004

    Article  Google Scholar 

  13. Choi J, Lee H-W, Suk K (2011) Increased plasma levels of lipocalin 2 in mild cognitive impairment. J Neurol Sci 305(1–2):28–33. https://doi.org/10.1016/j.jns.2011.03.023

    Article  CAS  PubMed  Google Scholar 

  14. Llorens F, Hermann P, Villar-Pique A, Diaz-Lucena D, Nagga K, Hansson O, Santana I, Schmitz M, Schmidt C, Varges D, Goebel S, Dumurgier J, Zetterberg H, Blennow K, Paquet C, Baldeiras I, Ferrer I, Zerr I (2020) Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nat Commun 11(1):619. https://doi.org/10.1038/s41467-020-14373-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ, Watts R, Anderson TJ (2010) The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 75(19):1717–1725. https://doi.org/10.1212/WNL.0b013e3181fc29c9

    Article  CAS  PubMed  Google Scholar 

  16. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184. https://doi.org/10.1136/jnnp.55.3.181

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson’s disease. J Neural Transm Suppl 60:277–290. https://doi.org/10.1007/978-3-7091-6301-6_19

    Article  Google Scholar 

  18. Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science (New York, NY) 353(6301):777–783. https://doi.org/10.1126/science.aag2590

    Article  CAS  Google Scholar 

  19. Xiao X, Yeoh BS, Vijay-Kumar M (2017) Lipocalin 2: an emerging player in iron homeostasis and inflammation. Annu Rev Nutr 37:103–130. https://doi.org/10.1146/annurev-nutr-071816-064559

    Article  CAS  PubMed  Google Scholar 

  20. Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D, Group F-Is (2018) Iron as a therapeutic target for Parkinson’s disease. Mov Disord 33(4):568–574. https://doi.org/10.1002/mds.27275

    Article  PubMed  Google Scholar 

  21. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. The Lancet Neurology 13(10):1045–1060. https://doi.org/10.1016/s1474-4422(14)70117-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Khalil M, Renner A, Langkammer C, Enzinger C, Ropele S, Stojakovic T, Scharnagl H, Bachmaier G, Pichler A, Archelos JJ, Fuchs S, Seifert-Held T, Fazekas F (2016) Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis. Mult Scler J 22(12):1560–1568. https://doi.org/10.1177/1352458515624560

    Article  CAS  Google Scholar 

  23. Berard JL, Zarruk JG, Arbour N, Prat A, Yong VW, Jacques FH, Akira S, David S (2012) Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis. Glia 60(7):1145–1159. https://doi.org/10.1002/glia.22342

    Article  PubMed  Google Scholar 

  24. Marques F, Mesquita SD, Sousa JC, Coppola G, Gao F, Geschwind DH, Columba-Cabezas S, Aloisi F, Degn M, Cerqueira JJ, Sousa N, Correia-Neves M, Palha JA (2012) Lipocalin 2 is present in the EAE brain and is modulated by natalizumab. Front Cell Neurosci 6:33. https://doi.org/10.3389/fncel.2012.00033

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ferreira AC, Pinto V, Da Mesquita S, Novais A, Sousa JC, Correia-Neves M, Sousa N, Palha JA, Marques F (2013) Lipocalin-2 is involved in emotional behaviors and cognitive function. Front Cell Neurosci 7:122. https://doi.org/10.3389/fncel.2013.00122

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Xingjian Wen for his assistance in language editing.

Author information

Authors and Affiliations

  1. Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuzhong District, Chongqing, 400016, China

    Mi Xiong, Qian Qian, Xue Liang & You-Dong Wei

  2. Chongqing Key Laboratory of Neurobiology, Chongqing, China

    You-Dong Wei

Authors
  1. Mi Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qian Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xue Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. You-Dong Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to You-Dong Wei.

Ethics declarations

Ethical approval

Our research was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University.

Informed consent

Written informed consent of all participants was obtained.

Conflict of interest

The authors declare no competting interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xiong, M., Qian, Q., Liang, X. et al. Serum levels of lipocalin-2 in patients with Parkinson’s disease. Neurol Sci 43, 1755–1759 (2022). https://doi.org/10.1007/s10072-021-05579-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-021-05579-3

Keywords

Search

Navigation